Deka Bank Deutsche Girozentrale Macrogenics Inc Transaction History

Deka Bank Deutsche Girozentrale

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$2.25 - $9.99 $41,175 - $182,817	-18,300 Closed	0 $0
Q1 2022 Apr 28, 2022	BUY	$8.12 - $16.9 $13,803 - $28,729	1,700 Added 10.24%	18,300 $162,000
Q4 2021 Feb 02, 2022	BUY	$15.91 - $21.88 $6,364 - $8,752	400 Added 2.47%	16,600 $261,000
Q4 2020 Mar 12, 2021	BUY	$19.41 - $26.0 $120,342 - $161,200	6,200 Added 62.0%	16,200 $363,000
Q3 2020 Oct 29, 2020	BUY	$24.69 - $31.6 $246,900 - $316,000	10,000 New	10,000 $251,000
Q2 2019 Aug 01, 2019	SELL	$14.51 - $19.71 $2.81 Million - $3.82 Million	-193,600 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$11.11 - $25.6 $1.99 Million - $4.59 Million	179,300 Added 1253.85%	193,600 $4.33 Million
Q4 2018 Feb 12, 2019	SELL	$11.75 - $21.42 $2.11 Million - $3.84 Million	-179,300 Reduced 92.61%	14,300 $180,000
Q3 2018 Nov 09, 2018	BUY	$19.26 - $23.46 $3.38 Million - $4.12 Million	175,500 Added 969.61%	193,600 $0
Q1 2018 May 03, 2018	SELL	$18.89 - $32.46 $3.97 Million - $6.83 Million	-210,400 Reduced 92.08%	18,100 $426,000
Q3 2017 Nov 06, 2017	BUY	$15.52 - $18.94 $3.55 Million - $4.33 Million	228,500	228,500 $3.75 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.